About
Profile
Listed on NASDAQ since 1991 and a member of the S&P 500®, IDEXX Laboratories, Inc. (IDXX) is the global leader in veterinary diagnostics, software, and water microbiology testing.
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
IDXX
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- IDEXX Laboratories beats top-line and bottom-line estimates; initiates FY24 outlook
- IDEXX Laboratories Q4 2023 Earnings Preview
- Piper Sandler downgrades Idexx to neutral, cites macro headwinds
- AMZN, WDC and others could see post-earnings boost - Morgan Stanley's Mike Wilson
- Top high-quality growth stocks poised to outperform - MS
- Goldman Sachs 2024 stock strategy - sales growth
- Goldman Sachs 2024 stock strategy - high quality
- IDEXX Labs slips after cutting full year revenue guidance, sees softness in clinic visits
- IDEXX Laboratories GAAP EPS of $2.53 beats by $0.16, revenue of $916M misses by $11.31M
- IDEXX Laboratories Q3 2023 Earnings Preview
- First U.S. bird flu case detected from commercial farm since April
- IDEXX Laboratories Non-GAAP EPS of $2.70 beats by $0.23, revenue of $943.63M beats by $9.58M
- IDEXX Laboratories Q2 2023 Earnings Preview
- IDEXX Laboratories beats Q1 estimates on top and bottom line, increases outlook
- IDEXX Laboratories Q1 2023 Earnings Preview
- China reports world’s first human death due to H3N8 bird flu – WHO
- IDEXX Laboratories Non-GAAP EPS of $2.07 beats by $0.15, revenue of $828.57M beats by $7.66M, initiates 2023 guidance
- U.S. avian flu outbreak worst in history
- IDEXX Laboratories rises on Q3 beat, narrows FY22 outlook on forex impact
- IDEXX Laboratories Non-GAAP EPS of $2.23 beats by $0.19, revenue of $841.66M beats by $11.66M